At AACR 2026, Abbott presented data on Cancerguard, a multi-biomarker blood-based MCED test that combines methylation and ...
FDA has accepted and granted Priority Review to the biologics license application for ifinatamab deruxtecan in adults with ...
TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...
Sarasota Memorial reported that 75% of lung cancers diagnosed through its early detection program were found at Stage I or II ...
Illumina and D3b, have announced a new data partnership aimed at accelerating research in pediatric cancer and rare disease, ...
Partner Therapeutics has submitted a supplemental Biologics License Application to the U.S. FDA for BIZENGRI, ...
Daraxonrasib significantly improved outcomes in the Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer, meeting all primary and key secondary endpoints. In the ...
BioNTech and DualityBio reported encouraging Phase 2 results for trastuzumab pamirtecan, an investigational HER2-targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results